<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139890</url>
  </required_header>
  <id_info>
    <org_study_id>METC 17-3-012</org_study_id>
    <nct_id>NCT03139890</nct_id>
  </id_info>
  <brief_title>Macronutrients and Postprandial Vascular Function</brief_title>
  <official_title>The Effects of Macronutrients on Postprandial Vascular Function in Overweight and Slightly Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular function decreases following the intake of a mixed meal in some, but not all&#xD;
      studies. Differences in the relative amounts of dietary fat, carbohydrates and protein&#xD;
      present in the mixed-meal challenges may have contributed to these apparently inconsistent&#xD;
      results. Well-designed trials - comparing under rigorously standardized conditions - on the&#xD;
      effects of macronutrients on postprandial vascular function are missing. The primary&#xD;
      objective of the current study is thus to evaluate in overweight and slightly obese men the&#xD;
      effects of the three macronutrients (fat, carbohydrates, and protein) on postprandial&#xD;
      vascular function, as assessed by brachial artery flow-mediated vasodilation (FMD). Secondary&#xD;
      objectives are to examine postprandial effects on other markers reflecting vascular function,&#xD;
      plasma markers for low-grade systemic inflammation and endothelial dysfunction, blood&#xD;
      pressure, and serum lipid and plasma glucose metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">September 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular endothelial function</measure>
    <time_frame>Change from baseline at 2 hours after milkshake consumption</time_frame>
    <description>Flow-mediated vasodilation (FMD) of the brachial artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular function markers</measure>
    <time_frame>Change from baseline at 2 hours after milkshake consumption</time_frame>
    <description>Carotid-femoral pulse wave velocity (PWV), pulse wave analysis (PWA), retinal microvascular caliber</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk markers</measure>
    <time_frame>Change from baseline at 2 hours after milkshake consumption</time_frame>
    <description>Plasma markers for low-grade systemic inflammation and endothelial dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk markers</measure>
    <time_frame>During 4 hours following milkshake consumption</time_frame>
    <description>Office blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial metabolism</measure>
    <time_frame>During 4 hours following milkshake consumption</time_frame>
    <description>Serum lipid and plasma glucose metabolism</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dietary Fats</condition>
  <condition>Carbohydrates</condition>
  <condition>Proteins</condition>
  <condition>Macronutrients</condition>
  <condition>Vascular Function</condition>
  <condition>Postprandial Metabolism</condition>
  <arm_group>
    <arm_group_label>High-fat milkshake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-carbohydrate milkshake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-protein milkshake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-fat (HF-LC-LP) milkshake</intervention_name>
    <description>During this experimental day, men will receive a high-fat milkshake</description>
    <arm_group_label>High-fat milkshake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-carbohydrate (LF-HC-LP) milkshake</intervention_name>
    <description>During this experimental day, men will receive a high-carbohydrate milkshake</description>
    <arm_group_label>High-carbohydrate milkshake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-protein (LF-LC-HP) milkshake</intervention_name>
    <description>During this experimental day, men will receive a high-protein milkshake</description>
    <arm_group_label>High-protein milkshake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18-70 years&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  BMI between 25-35 kg/m2 (overweight and slightly obese)&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 7.0 mmol/L&#xD;
&#xD;
          -  Fasting serum total cholesterol &lt; 8.0 mmol/L&#xD;
&#xD;
          -  Fasting serum triacylglycerol &lt; 2.2 mmol/L&#xD;
&#xD;
          -  Systolic blood pressure &lt; 160 mmHg and diastolic blood pressure &lt; 100 mmHg&#xD;
&#xD;
          -  No current smoker&#xD;
&#xD;
          -  No diabetic patients&#xD;
&#xD;
          -  No familial hypercholesterolemia&#xD;
&#xD;
          -  No abuse of drugs&#xD;
&#xD;
          -  No more than 3 alcoholic consumptions per day&#xD;
&#xD;
          -  Stable body weight (weight gain or loss &lt; 3 kg in the past three months)&#xD;
&#xD;
          -  No use of dietary supplements known to interfere with the main study outcomes as&#xD;
             judged by the principal investigator&#xD;
&#xD;
          -  No use of medication to treat blood pressure, lipid or glucose metabolism&#xD;
&#xD;
          -  No use of an investigational product within another biomedical intervention trial&#xD;
             within the previous 1-month&#xD;
&#xD;
          -  No severe medical conditions that might interfere with the study, such as epilepsy,&#xD;
             asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease,&#xD;
             inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis&#xD;
&#xD;
          -  No active cardiovascular disease like congestive heart failure or cardiovascular&#xD;
             event, such as an acute myocardial infarction or cerebrovascular accident&#xD;
&#xD;
          -  Willingness to give up being a blood donor from 8 weeks before the start of the study,&#xD;
             during the study and for 4 weeks after completion of the study&#xD;
&#xD;
          -  No difficult venipuncture as evidenced during the screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women&#xD;
&#xD;
          -  Fasting plasma glucose ≥ 7.0 mmol/L&#xD;
&#xD;
          -  Fasting serum total cholesterol ≥ 8.0 mmol/L&#xD;
&#xD;
          -  Fasting serum triacylglycerol ≥ 2.2 mmol/L&#xD;
&#xD;
          -  Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg&#xD;
&#xD;
          -  Current smoker, or smoking cessation &lt; 12 months&#xD;
&#xD;
          -  Diabetic patients&#xD;
&#xD;
          -  Familial hypercholesterolemia&#xD;
&#xD;
          -  Abuse of drugs&#xD;
&#xD;
          -  More than 3 alcoholic consumptions per day&#xD;
&#xD;
          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past three months)&#xD;
&#xD;
          -  Use of dietary supplements known to interfere with the main study outcomes as judged&#xD;
             by the principal investigator&#xD;
&#xD;
          -  Use medication to treat blood pressure, lipid or glucose metabolism&#xD;
&#xD;
          -  Use of an investigational product within another biomedical intervention trial within&#xD;
             the previous 1-month&#xD;
&#xD;
          -  Severe medical conditions that might interfere with the study, such as epilepsy,&#xD;
             asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease,&#xD;
             inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis&#xD;
&#xD;
          -  Active cardiovascular disease like congestive heart failure or cardiovascular event,&#xD;
             such as an acute myocardial infarction or cerebrovascular accident&#xD;
&#xD;
          -  Not willing to give up being a blood donor from 8 weeks before the start of the study,&#xD;
             during the study or for 4 weeks after completion of the study&#xD;
&#xD;
          -  Not or difficult to venipuncture as evidenced during the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Joris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

